58 related articles for article (PubMed ID: 30539751)
1. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
[TBL] [Abstract][Full Text] [Related]
2. Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer.
Li J
Ann Ital Chir; 2024; 95(2):246-252. PubMed ID: 38684494
[TBL] [Abstract][Full Text] [Related]
3. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.
Wang CC; Tsai YC; Jeng YM
PLoS One; 2019; 14(8):e0221785. PubMed ID: 31469885
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
[TBL] [Abstract][Full Text] [Related]
5. Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.
Schallenberg S; Plage H; Hofbauer S; Furlano K; Weinberger S; Bruch PG; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Horst D; Klatte T; Schlomm T; Zecha H
Acta Oncol; 2023 Dec; 62(12):1880-1889. PubMed ID: 37938166
[TBL] [Abstract][Full Text] [Related]
6. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.
Teo MTW; Dyrskjøt L; Nsengimana J; Buchwald C; Snowden H; Morgan J; Jensen JB; Knowles MA; Taylor G; Barrett JH; Borre M; Ørntoft TF; Bishop DT; Kiltie AE
Ann Oncol; 2014 Apr; 25(4):877-883. PubMed ID: 24623370
[TBL] [Abstract][Full Text] [Related]
9. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy.
Mo Q; Li R; Adeegbe DO; Peng G; Chan KS
Commun Biol; 2020 Dec; 3(1):784. PubMed ID: 33335285
[TBL] [Abstract][Full Text] [Related]
10. The prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer.
Demirci A; Ordu M
Indian J Pathol Microbiol; 2023; 66(3):502-510. PubMed ID: 37530330
[TBL] [Abstract][Full Text] [Related]
11. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
Lebret T; Bonastre J; Fraslin A; Neuzillet Y; Droupy S; Rebillard X; Vordos D; Guy L; Villers A; Schneider M; Coloby P; Lacoste J; Méjean A; Lacoste J; Descotes JL; Eschwege P; Loison G; Blanché H; Mariani O; Ghaleh B; Mangin A; Sirab N; Groussard K; Radvanyi F; Allory Y; Benhamou S
BMJ Open; 2023 Dec; 13(12):e075942. PubMed ID: 38128940
[TBL] [Abstract][Full Text] [Related]
12. Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.
Lozano-Leon A; Perez-Quintela BV; Iglesias-García J; Lariño-Noia J; Varo E; Forteza J; Domínguez-Muñoz JE
Oncol Lett; 2011 Jan; 2(1):161-166. PubMed ID: 22870146
[TBL] [Abstract][Full Text] [Related]
13. p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors.
Nasir A; Ahmed MK; Saller JJ; Henderson-Jackson EB; Malafa MP; Yeatman TJ; Coppola D
Cancer Genomics Proteomics; 2023; 20(6):522-530. PubMed ID: 37889062
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics in bladder cancer.
Dancik GM; Theodorescu D
Urol Oncol; 2014 Jan; 32(1):16-22. PubMed ID: 24360659
[TBL] [Abstract][Full Text] [Related]
15. MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
Walker AK; Karaszi K; Valentine H; Strauss VY; Choudhury A; McGill S; Wen K; Brown MD; Ramani V; Bhattarai S; Teo MTW; Yang L; Myers KA; Deshmukh N; Denley H; Browning L; Love SB; Iyer G; Clarke NW; Hall E; Huddart R; James ND; Hoskin PJ; West CML; Kiltie AE
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):809-818. PubMed ID: 30885775
[TBL] [Abstract][Full Text] [Related]
16. p21 as a Predictor and Prognostic Indicator of Clinical Outcome in Rectal Cancer Patients.
Ooi LC; Ho V; Zhu JZ; Lim S; Chung L; Abubakar A; Rutland T; Chua W; Ng W; Lee M; Morgan M; MacKenzie S; Lee CS
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255799
[TBL] [Abstract][Full Text] [Related]
17. ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer.
Omura M; Kosaka T; Kobayashi H; Shigeta K; Matsumoto K; Hara S; Kikuchi E; Mikami S; Saya H; Sato Y; Oya M
Ann Surg Oncol; 2024 Jun; 31(6):3914-3915. PubMed ID: 38564070
[No Abstract] [Full Text] [Related]
18. Special Issue: Cancer Metabolism.
Basetti M
Metabolites; 2017 Aug; 7(3):. PubMed ID: 28792436
[TBL] [Abstract][Full Text] [Related]
19. A Conversation with ChatGPT on Contentious Issues in Senescence and Cancer Research.
Elshazly AM; Shahin U; Al Shboul S; Gewirtz DA; Saleh T
Mol Pharmacol; 2024 Apr; 105(5):313-327. PubMed ID: 38458774
[TBL] [Abstract][Full Text] [Related]
20. Bioactive peptides for anticancer therapies.
Zhang Y; Wang C; Zhang W; Li X
Biomater Transl; 2023; 4(1):5-17. PubMed ID: 37206303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
